These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 24506960)

  • 1. [Expression of PD-1/PD-L1 in peripheral blood mononuclear cells in lung cancer patients and its biological significance].
    Xu P; Chen H; Chen YJ; Chen YB; Gu GH; Wu MY; Wu MJ; Wang XF; Zhang XG
    Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):910-3. PubMed ID: 24506960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of soluble PD-L1 released by lung cancer cells in regulating the function of T lymphocytes].
    Shi MH; Xing YF; Zhang ZL; Huang JA; Chen YJ
    Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):85-8. PubMed ID: 23714659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased PD-1 on CD4(+)CD28(-) T cell and soluble PD-1 ligand-1 in patients with T2DM: association with atherosclerotic macrovascular diseases.
    Shi B; Du X; Wang Q; Chen Y; Zhang X
    Metabolism; 2013 Jun; 62(6):778-85. PubMed ID: 23398844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.
    Meniawy TM; Lake RA; McDonnell AM; Millward MJ; Nowak AK
    Lung Cancer; 2016 Mar; 93():9-16. PubMed ID: 26898608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer].
    Li H; Liu Y; Liu Y; Liu J; Zhao D; Wang Y; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):755-760. PubMed ID: 29167005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
    Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
    J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
    Ikeda S; Okamoto T; Okano S; Umemoto Y; Tagawa T; Morodomi Y; Kohno M; Shimamatsu S; Kitahara H; Suzuki Y; Fujishita T; Maehara Y
    J Thorac Oncol; 2016 Jan; 11(1):62-71. PubMed ID: 26762740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of PD-1 and PD-L1 in the peripheral blood of advanced non-small-cell lung cancer patients and its implications].
    Xing YF; Pan X; Qian B; Shi MH
    Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):111-114. PubMed ID: 30669748
    [No Abstract]   [Full Text] [Related]  

  • 10. [Increased expressions of programmed death 1 (PD-1) and its ligands in peripheral CD3(+) T cells and CD19(+) B cells in patients with hepatocellular carcinoma].
    Liu W; Chai L; Liang J; Lu Z; Yang S
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Sep; 32(9):1243-7. PubMed ID: 27609582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The increase of circulating PD-L1-expressing CD68(+) macrophage in ovarian cancer.
    Qu QX; Huang Q; Shen Y; Zhu YB; Zhang XG
    Tumour Biol; 2016 Apr; 37(4):5031-7. PubMed ID: 26541760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.
    Prosser ME; Brown CE; Shami AF; Forman SJ; Jensen MC
    Mol Immunol; 2012 Jul; 51(3-4):263-72. PubMed ID: 22503210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
    Shao N; Cai Q
    Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic.
    Oguejiofor K; Galletta-Williams H; Dovedi SJ; Roberts DL; Stern PL; West CM
    Oncotarget; 2017 Feb; 8(9):14416-14427. PubMed ID: 28122336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The level of soluble programmed death-1 in peripheral blood of patients with lung cancer and its clinical implications].
    Xing YF; Zhang ZL; Shi MH; Ma Y; Chen YJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):102-6. PubMed ID: 22455965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
    Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
    Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1/PD-L1 signal pathway participates in HCV F protein-induced T cell dysfunction in chronic HCV infection.
    Xiao W; Jiang LF; Deng XZ; Zhu DY; Pei JP; Xu ML; Li BJ; Wang CJ; Zhang JH; Zhang Q; Zhou ZX; Ding WL; Xu XD; Yue M
    Immunol Res; 2016 Apr; 64(2):412-23. PubMed ID: 26286967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].
    Ren T; Cai YY; Liang YJ; Jin ML; Guo ZL; Tao MF; He X
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(17):1168-72. PubMed ID: 18844109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
    Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.